Indaptus Therapeutics completes note conversion and obtains stockholder approval for private placement issuance

Indaptus Therapeutics, Inc.

Raised gross proceeds of approximately $5.7 million in private placement of convertible notes and warrants, closed June 12 and June 30, 2025.
On July 27, 2025, notes automatically converted into 545,598 common shares at $8.3024 per share; issued 1,384,722 warrants exercisable at same price.
Also issued pre-funded warrants for 146,763 shares and placement agent warrants for 83,083 shares to Paulson Investment Company.
At special meeting on July 25, 2025, shareholders approved issuance by 225,534 votes for (95.2%) and 225,161 votes for related-party issuance.
Total votes represented 41.35% of outstanding shares, with quorum achieved; both proposals passed with overwhelming majority.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.